Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

methotrexate

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor

Related drugs:

‹

pemetrexed (58)

pralatrexate (2)

methotrexate oral solution (0)

methotrexate IV (0)

pemetrexed (58)

pralatrexate (2)

methotrexate oral solution (0)

methotrexate IV (0)

›

No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	methotrexate Sensitive: A1 - Approval methotrexate Sensitive : A1	methotrexate Sensitive: A1 - Approval methotrexate Sensitive : A1
No biomarker	Oral Cancer	No biomarker	Oral Cancer	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	cytarabine + methotrexate Sensitive: A2 - Guideline cytarabine + methotrexate Sensitive : A2	cytarabine + methotrexate Sensitive: A2 - Guideline cytarabine + methotrexate Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	cytarabine + methotrexate + idarubicin Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin Sensitive : A2	cytarabine + methotrexate + idarubicin Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin Sensitive : A2